A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA

Table 7

Change from baseline in WOMAC stiffness score.

Visits	Curene® 500mg		Placebo
	N=25		N=25
	Mean (SD)	Change from baseline	Mean (SD)	Change from baseline
Baseline (Day 0)	4.52±0.92		4.72±1.02
Visit 2 (Day 7)	4.16±1.07	0.36±0.49	4.64±0.91	0.08±0.57
Visit 3 (Day 15)	3.52±0.96	1±0.58	4.4±0.87	0.32±0.63
Visit 4 (Day 30)	2.84±1.07	1.68±0.63	4±0.91	0.72±0.61
Visit 5 (Day 60)	2.12±0.97	2.4±0.82	3.76±1.09	0.96±0.68

Statistically significant (P <0.05) within group; statistically significant (P <0.05) between group.
Within group analysis by Pair t-test and between group analysis by repeated measures ANCOVA.